Use of Nebulized Amphotericin B in the Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis

Table 1

	Current age (years)	Age at Λ; (months)	Age at first ABPA diagnosis (years)	Sweat Cl; (meq/l)	Genotype	Airway bacterial pathogens during ABPA	Indication for; inhaled AMB	Other medica issues
1 (f)	7	11	5.5	106	1717−1G>A/g.3464_3471dup; TCATTGCT and V1198M	SA, SM, AX, Chronic PA (age 6)	1	ICS
2( f)	11	4	8	85	F508del/F508del	SA, AX,	1, 2	ICS, Nissen
3(m)	13	2	8	90	F508del/?	B. cepacia (age 8)	2, 3
4 (f)	16	7	10	98	F508del/R553X	Chronic PA (age 10), MAC (age 11)	2, 3, 4	MAC,; gastrostomy, DM
5 (f)	19	36	7	120	F508del/F508del	SA, HI, SM	2, 3	DM
6 (f)	20	1 (NS)	11	?	F508del/F508del	Chronic PA (age 16)	2, 3	Nissen
7 (f)	20	At birth	9	95	F508del/F508del	Chronic PA (age 5)	2, 3	MI, DM